Holland-based blockchain startup Triall reportedly disclosed details of its alliance forged with US nonprofit medical facility Mayo Clinic to optimize clinical trial design and the management of study data. 

Specifically, beginning September 2022, Triall’s eClinical platform will reportedly offer faclitation for a two-year multi-center pulmonary arterial hypertension clinical trial, which covers 10 research sites and over 500 patients throughout America. 

The software will offer assistance for numerous activities, nominally data capture, document management, study monitoring and consent. Per Triall, the partnership was reportedly formed with a goal of showcasing an immutable public ledger audit trail via blockchain, to streamline the integrity of clinical trials. 

Investigators, regulators and stakeholders will then be able to review and run assessments for that kind of trial-associated data with trust, knowing that no individual can modify the records.

In the U.S., the median cost of a clinical trial investigating new drugs or therapies falls at around $19 million. Approval rates for new chemical entities and biologics typically hover between 10% and 20% from the preclinical phase to finish and can often take years of investigation.

Introduced in 2018, Triall has reportedly activated commercialization for its first blockchain offering – Verial eTMF, making it possible for researchers to generate verifiable proofs of authenticity of the clinical trial documents, like patient diagnosis data. 

Furthermore, the company is investing resources in designing APIs via eClinical which allows for current third-party clinical trial software providers to link up with Triall’s blockchain infrastructure. 

The native TRL token is reportedly built to cater to ecosystem utility, nominally paying compensation to clinical trial participants. Should the project be a success, Triall aims for further collaboration with the Mayo Clinic in the realm of decentralized medical research.